Sage Therapeutics to end development of key therapy after a third trial failure

It was the third failed trial for the therapy, called dalzanemdor, which also failed to meet its goals in a Phase 2 trial as a treatment for mild cognitive impairment and mild dementia in Alzheimer’s disease.

Read more at MarketWatch

Save story

Topics

Related

Viking Therapeutics’ weight-loss pill shows ‘great outcome’ in trial
Business - MarketWatch - November 4
Man's brain tumour shrinks by half in therapy trial
Top stories - BBC News - October 29
Biden administration to restrict drilling, renewables in the US West to help struggling bird
Tech - ABC News - November 8
23andMe to slash 40% of its workforce, end therapeutics program to cut costs
Business - MarketWatch - November 12
Sage shares surge 19% as UK software group launches buyback
World - Financial Times - 8 hours ago
Twins with heart failure cannot get the same treatment because of where they live
Top stories - BBC News - 3 days ago

More from MarketWatch

Why Qualcomm’s latest diversification plans aren’t enough to help its stock
Business - MarketWatch - 20 minutes ago
Risk of conflict between Trump and the Fed ‘is very high,’ top economist Blanchard says
Business - MarketWatch - 29 minutes ago
This Roth strategy lets elite savers stash $70,000 in their 401(k) in 2025
Business - MarketWatch - 55 minutes ago
Nvidia earnings will drive stocks tied to AI’s growth. Here’s what to look for.
Business - MarketWatch - 1 hour ago
Two powerful banking regulators say they won’t step down just because Trump won
Business - MarketWatch - 1 hour ago